Fluxion Biosciences Announces Launch of ERASE-Seq NGS Liquid Biopsy Analysis Service

Font : A-A+

Cloud-based ERASE-Seq delivers ultra-high sensitivity somatic mutation detection using background error correction and statistical noise reduction

ALAMEDA, Calif., Jan. 4, 2018 /PRNewswire/ -- Fluxion Biosciences announced today that its ERASE-Seq™ bioinformatics

solution can now be utilized for variant calling from a wide range of targeted cancer panels. Until now, ERASE-Seq was limited to use on Fluxion's 59-gene Spotlight 59 Cancer Panel. ERASE-Seq is now available for use with Swift Biosciences' Accel Amplicon™ 56G panel and Illumina's TruSight® Tumor 15 panel. Other custom and commercial panels are also compatible with ERASE-Seq, and can be added following validation testing by Fluxion.

Liquid biopsies offer the potential to improve treatment of cancer by providing affordable, non-invasive detection of actionable cancer mutations from a blood sample. However, the relative abundance of cancer DNA in blood is extremely low, below the sensitivity threshold of standard sequencers. Approaches such as molecular barcodes have resulted in improved performance; however, high sensitivity and, importantly, high specificity have been difficult to achieve at allele frequencies between 0.1-0.5%. This is a critical region for somatic cancer variant detection in liquid biopsies, and ERASE-Seq provides far superior accuracy here compared to competitive approaches.

"Fluxion's ERASE-Seq bioinformatics solution utilizes statistical processing and background modeling to reduce both systematic (repeated) errors as well as random errors (noise), without the need for molecular barcodes (unique molecular IDs, or UMIs)," states Dr. Cristian Ionescu-Zanetti, CTO. "ERASE-Seq provides levels of performance unachievable with any other method- maintaining exceptional sensitivity and specificity to below 0.1% allele frequency. Our customers are very excited that they can now apply ERASE-Seq to existing panels that their lab has already adopted."

ERASE-Seq bioinformatic analyses for the Swift Biosciences 56G and Illumina TruSight Tumor 15 panels are available immediately via cloud-based analysis. ERASE-Seq is modular and can be optimized to different sequencing protocols, sensitivity targets, and input DNA quantities. Contact Fluxion for details.

About Fluxion BiosciencesFluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, the Spotlight 59 NGS Oncology Panel for ultra-sensitive mutation detection from CTCs and ctDNA, and the ERASE-Seq variant caller for liquid biopsies. Fluxion's technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion Biosciences' liquid biopsy capabilities, visit liquidbiopsy.fluxionbio.com

Contact:

Jeff Jensen650-241-4747188247@email4pr.com

View original content:http://www.prnewswire.com/news-releases/fluxion-biosciences-announces-launch-of-erase-seq-ngs-liquid-biopsy-analysis-service-300577497.html

SOURCE Fluxion Biosciences

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.